MADRIGAL PHARMACEUTICALS, INC. SEC Filings

Madrigal Pharmaceuticals (MDGL) notice reports a proposed sale under Rule 144 by an affiliate who acquired 2,900 common shares on 08/29/2025 by exercising options under a registered plan and intends to sell them through Morgan Stanley Smith Barney on 08/29/2025 on NASDAQ for an aggregate market value of $1,251,895.78. The filer lists the issuer's outstanding shares as 22,289,014. The form also discloses that the same person sold 7,100 shares in three transactions during August 2025, generating total gross proceeds of approximately $2,657,186.88. The signer certifies no undisclosed material adverse information.

William J. Sibold, President, CEO and Director of Madrigal Pharmaceuticals, Inc. (MDGL), reported sales of company common stock on 08/21/2025 executed under a Rule 10b5-1 trading plan adopted on 11/15/2024. The filing shows an automated sale of 6,485 shares at a weighted-average price of $400.0347, after which the reporting person beneficially owned 110,884 shares. A subsequent automated sale of 1,131 shares at a weighted-average price of $401.0003 reduced beneficial ownership to 109,753 shares. The reporting person signed the Form 4 through an attorney-in-fact on 08/21/2025. All sales are disclosed as having been effected automatically pursuant to the specified 10b5-1 plan and the filing provides weighted-average price ranges for the transactions.

Madrigal Pharmaceuticals (MDGL) filed a Form 144 notifying the proposed sale of 7,616 common shares through Morgan Stanley Smith Barney on 08/21/2025, with an aggregate market value listed as $2,982,882.56 and 22,289,014 shares outstanding. The securities were acquired on 09/08/2024 as Restricted Stock Units from the issuer, with payment/vesting dated 09/08/2024. The filer reports no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Madrigal Pharmaceuticals insiders associated with Baker Bros. reported multiple purchases of Common Stock on August 18 and August 20, 2025. The filings show a series of market purchases (transaction code P) executed at weighted-average prices ranging roughly from $372.59 to $392.57 per share. The reported entries record incremental increases in indirect beneficial ownership for Baker-related reporting persons and funds, with reported position levels shown in the filing as approximately 1,947,968 shares for one reported position and about 202,813 shares for another at various post-transaction lines. Footnotes explain these holdings are indirect and arise from the reporting persons' relationships to investment funds and the adviser, and that some shares reflect vested restricted stock units previously granted to directors.

Madrigal Pharmaceuticals insiders and affiliated funds reported multiple purchases of Common Stock on 08/18/2025. The filings show aggregated acquisitions executed in multiple transactions at weighted-average prices ranging roughly from $353.76 to $372.50 per share. Following the reported purchases, the filings list two classes of beneficial ownership totals: approximately 193,000 shares and approximately 1,859,091–1,848,963 shares across different line items, reflecting purchases by 667, L.P. and Baker Brothers Life Sciences, L.P., with Baker Bros. Advisors LP as adviser. Reporting persons include Baker Bros. entities, Julian C. Baker, Felix J. Baker and directors including Dr. Raymond Cheong. The filing is noted as the first of two Form 4s covering these changes.

Madrigal Pharmaceuticals, Inc. (MDGL) Rule 144 notice shows proposed and recent sales of common stock by an identified insider. The filing lists a proposed sale of 1,000 shares through Morgan Stanley Smith Barney with an aggregate market value of $390,224.20, slated for 08/20/2025 on NASDAQ. Those 1,000 shares were acquired the same day by exercise of options under a registered plan and paid in cash. The filer also reported prior sales by the same person in the past three months: 2,000 shares on 08/18/2025 for $764,481.20 and 4,100 shares on 08/15/2025 for $1,503,481.48. The notice includes the standard insider representation that no undisclosed material adverse information is known.

Madrigal Pharmaceuticals’ General Counsel Kelley Shannon T reported eight sales totaling 1,304 shares of Common Stock on August 18, 2025, at prices roughly between $358.66 and $376.62 per share. After these transactions she directly holds 9,173 shares. Footnotes note that part of the sales covered tax withholding on vesting restricted stock units, at least one sale was under a Rule 10b5-1 trading plan adopted November 7, 2024, and several prices reflect weighted-average ranges.

Madrigal Pharmaceuticals, Inc. (MDGL) Form 144 notice reports a proposed sale of securities by a person for whose account shares vested as restricted stock units. The filer plans to sell two lots of Common Stock through Morgan Stanley Smith Barney LLC on 08/18/2025: 458 shares (aggregate market value $169,386.72) and 846 shares (aggregate market value $312,884.64). Both lots were acquired on 08/15/2025 by vesting of restricted stock units from the issuer. The filing states there were no sales by the filer in the prior three months and includes the required attestation about material nonpublic information.

Madrigal Pharmaceuticals (MDGL) Form 144 filing shows a proposed sale of 2,000 common shares to be executed through Morgan Stanley Smith Barney on 08/18/2025 with an aggregate market value of $764,481.20. The filer states these 2,000 shares were acquired the same day by exercise of options under a registered plan and paid in cash. The filing also discloses that the same person sold 4,100 shares on 08/15/2025 for gross proceeds of $1,503,481.48. The filer signs a representation that they are unaware of any undisclosed material adverse information about the issuer.